血液透析治疗时长与死亡率和住院率的关联:大型队列研究
该回顾性队列纳入146,127例维持性中心血液透析患者,按平均治疗时长分为6组(180-269分钟),随访1年。与180-194分钟组相比,240-254分钟组全因死亡风险降低27%(HR 0.73 [0.69-0.76]),且住院率和住院时长也呈相似改善趋势。
要点
- 较长透析治疗时长(至240-254分钟)与更低的全因死亡风险相关。
- 生存获益在平均超滤量和spKt/V > 1.4的患者中均观察到。
- 较长治疗时长还与更低的住院率和更短的住院时长相关。
核心结论
- 较长透析治疗时长与更好的生存、更少住院和更短住院时长相关。
- 即使考虑超滤量和spKt/V > 1.4,生存获益仍然存在。
研究设计与样本
- 回顾性队列研究,纳入146,127例18-89岁维持性中心血液透析患者,透析时间2022年1月1日至2023年7月1日,30天导入期后随访1年。
- 按暴露期平均治疗时长分为6组:180-194、195-209、210-224、225-239、240-254和255-269分钟。
主要发现
- 与180-194分钟组相比,240-254分钟组全因死亡风险降低27%(HR 0.73 [0.69-0.76])。
- 210-224分钟组和225-239分钟组全因死亡风险均降低19%(HR 0.81 [0.77-0.85])。
- 195-209分钟组全因死亡风险降低15%。
- 生存获益在平均超滤量较宽范围和spKt/V > 1.4的患者中观察到,但spKt/V < 1.4者未观察到。
- 较长治疗时长(至240-254分钟)与更低的住院率和更短的住院时长相关。
临床怎么用
- 在临床允许的情况下,可考虑将透析治疗时长延长至240-254分钟以改善生存和减少住院。
- 评估治疗时长获益时需结合spKt/V,spKt/V < 1.4的患者可能不从延长治疗时长中获益。
局限性
- 存在选择偏倚的可能性,不能排除。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The relationship between hemodialysis treatment time, hospitalization rates, and mortality remains an area of controversy because of difficulties in separating the clinical effects of treatment time from urea clearance and ultrafiltration (UF) volume. METHODS: Data were obtained from a retrospective cohort of 146,127 maintenance in-center hemodialysis patients, aged 18 to 89 years, who dialyzed at Fresenius Kidney Care (FKC) clinics between January 1, 2022 and July 1, 2023 with 1-year follow-up after a 30-day run-in period. The patients were stratified into 6 treatment-time groups based on their mean delivered treatment time during the exposure period (180-194, 195-209, 210-224, 225-239, 240-254, and 255-269 minutes). The primary outcome was all-cause mortality; secondary outcomes included all-cause hospitalization rates and hospital length of stay. RESULTS: Mean dialysis vintage was > 4 years, and few patients likely had residual kidney function. Compared with individuals in the 180-194 minutes group, patients in the 240-254 minutes group had a 27% lower mortality (hazard ratio: 0.73 [0.69-0.76]), whereas patients in the 210-224 minutes and 225-239 minutes groups both had a 19% lower mortality (hazard ratio: 0.81 [0.77-0.85]) and 195-209 minutes group had 15%. These benefits were observed in patient subgroups across a wide range of mean UF volumes as well as with a spKt/V > 1.4, but not for patients with spKt/V < 1.4. In secondary analyses, similar associations were observed between longer treatment times (up to 240-254 minutes) and reduced hospitalization rates and shorter hospital stays. CONCLUSION: Longer dialysis treatment times are associated with better survival, fewer hospitalizations, and shorter hospital stays. Although the potential for selection bias cannot be excluded, these survival benefits were realized even when accounting for UF volume and spKt/V > 1.4.
引用
- Lasky R, Ficociello LH, Flythe JE, et al. The Associations Between Dialysis Treatment Time, Mortality, and Hospitalizations in a Large Hemodialysis Cohort. Kidney Int Rep. 2026. PMID: 42022337. doi:10.1016/j.ekir.2026.106483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。